GLP-1 fusion peptides, their production and use
First Claim
1. A fusion peptide comprising as component (I) N-terminally a sequence according to formula I
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala -Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-X
-
(I),wherein X is NH2 or Gly-OH, or a sequence having at least 95% sequence identity with the sequence according to formula I; and
as component (II) C-terminally a peptide sequence containing SEQ ID NO;
26 or a sequence having at least 90% sequence identity with SEQ ID NO;
26, and its pharmaceutically active salts,wherein the fusion peptide has insulinotropic activity.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II)C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.
-
Citations
25 Claims
-
1. A fusion peptide comprising as component (I) N-terminally a sequence according to formula I
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala -Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-X-
(I),wherein X is NH2 or Gly-OH, or a sequence having at least 95% sequence identity with the sequence according to formula I; and as component (II) C-terminally a peptide sequence containing SEQ ID NO;
26 or a sequence having at least 90% sequence identity with SEQ ID NO;
26, and its pharmaceutically active salts,wherein the fusion peptide has insulinotropic activity. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
Specification